The Global Landscape of Personalized Cancer Vaccines: 199 Trials and Counting | Research

The takeaway

Analysis of 199 clinical trials shows neoantigen cancer vaccines are rapidly advancing, with peptide vaccines dominating (64.8%), a shift toward DC and liposomal delivery platforms, and increasing combination with immune checkpoint inhibitors.

199 clinical trials, 64.8% peptide-based
The global landscape of personalized neoantigen cancer vaccines shows rapid growth, with peptide vaccines leading but delivery platforms evolving toward DC systems and lipid nanoparticles

What the researchers found

Of 199 neoantigen vaccine clinical trials, peptide vaccines dominate (64.8%), delivery platforms are shifting toward DC systems (16.1%) and LNP/LPX (11%), most trials are Phase I (59.8%), and combination with immune checkpoint inhibitors is the primary development strategy.

Why it matters

Personalized cancer vaccines represent one of the most promising frontiers in oncology — targeting each patient's unique tumor mutations. This comprehensive landscape analysis helps researchers, investors, and patients understand where the field stands and where it's heading.

The numbers in context

Review covers clinical trials globally from the Trialtrove database, spanning multiple vaccine platforms and cancer types.

How the study worked

Retrospective analysis of the Trialtrove database for all personalized neoantigen vaccine clinical trials initiated through December 2022. Analyzed by phase, sponsor type, host country, treatment modality, combination strategy, delivery platform, and cancer type.

Who was studied

Global clinical trial participants across cancer types

What this study cannot tell us

Database analysis can't assess trial quality or results — only counts and characteristics. Many trials are early-phase with unknown outcomes. The rapid pace of the field means the landscape may have changed significantly since the December 2022 cutoff. Peptide vaccine dominance by count may not reflect clinical efficacy rankings.

How to read the evidence

Moderate evidence as a comprehensive database analysis of clinical trial activity. Provides a valuable overview of the field but doesn't assess trial outcomes or vaccine efficacy.

When this study was published

Published in 2024 with data through December 2022. The field is evolving rapidly — several significant results have emerged since the cutoff date.

The bigger picture

Personalized cancer vaccines are at an inflection point. The mRNA vaccine technology accelerated by COVID-19 is now being applied to cancer (Moderna's mRNA-4157 showed promising Phase II results with pembrolizumab in melanoma). Combined with AI-driven neoantigen prediction, cheaper sequencing, and better delivery platforms, the next few years could see breakthrough Phase III results that transform cancer treatment.

Questions still open

Which delivery platform (peptide, mRNA, DC) will ultimately prove most effective for neoantigen vaccines?
Can neoantigen vaccines move beyond maintenance/adjuvant therapy to become primary cancer treatments?
Will AI-driven neoantigen prediction algorithms improve vaccine success rates in upcoming Phase III trials?

Common questions

What is a neoantigen cancer vaccine and how is it personalized?

Every person's cancer carries unique mutations that produce abnormal proteins (neoantigens) found only in their tumor cells. A personalized neoantigen vaccine sequences the patient's tumor DNA, identifies these unique mutations, synthesizes peptides or mRNA matching them, and trains the patient's immune system to attack cells displaying those specific neoantigens. It's truly one-of-a-kind treatment — no two patients receive the same vaccine.

Are personalized cancer vaccines available now?

They're mostly available through clinical trials, not as approved treatments. Most trials are still Phase I (59.8%), meaning they're primarily testing safety and dosing. However, some promising Phase II results have emerged, particularly combining neoantigen vaccines with immune checkpoint inhibitors. The field is advancing rapidly, and Phase III trials that could lead to approval are expected in the coming years.

Read the original research

Personalized neoantigen cancer vaccines: current progression, challenges and a bright future.

Clinical and experimental medicine, 24(1), 229

View on PubMed ↗Publisher’s paper ↗

Citation

Wu, Da-Wei; Jia, Shuo-Peng; Xing, Shu-Jun; Ma, Hai-Lan; Wang, Xin; Tang, Qi-Yu; Li, Zi-Wei; Wu, Qing; Bai, Min; Zhang, Xin-Yong; Fu, Xiao-Feng; Jia, Ming-Ming; Tang, Yu; Chen, Li; Li, Ning. (2024). Personalized neoantigen cancer vaccines: current progression, challenges and a bright future.. Clinical and experimental medicine, 24(1), 229. https://doi.org/10.1007/s10238-024-01436-7